Interleukin-6, procalcitonin and neutrophil-to-lymphocyte ratio: Potential immune-inflammatory parameters to identify severe and fatal forms of COVID-19.


Journal

Cytokine
ISSN: 1096-0023
Titre abrégé: Cytokine
Pays: England
ID NLM: 9005353

Informations de publication

Date de publication:
05 2021
Historique:
received: 15 09 2020
revised: 08 01 2021
accepted: 09 01 2021
pubmed: 8 2 2021
medline: 30 3 2021
entrez: 7 2 2021
Statut: ppublish

Résumé

Accumulating evidence supports that the viral-induced hyper-inflammatory immune response plays a central role in COVID-19 pathogenesis. It might be involved in the progression to acute respiratory distress syndrome (ARDS), multi-organ failure leading to death. In this study, we aimed to evaluate the prognostic value of the immune-inflammatory biomarkers in COVID-19, then determine optimal thresholds for assessing severe and fatal forms of this disease.153 patients with confirmed COVID-19 were included in this study, and classified into non-severe and severe groups. Plasmatic levels of interleukin 6 (IL6), C-reactive protein (CRP), soluble-IL2 receptor (IL2Rα), procalcitonin (PCT) and ferritin were measured using chemiluminescence assay. Complete blood count was performed by Convergys 3X® hematology analyzer. Our results demonstrated that the peripheral blood levels of IL6, PCT, CRP, ferritin, IL2Rα, white blood cell count (WBC), neutrophil count (NEU), neutrophil-to-lymphocyte ratio (NLR), derived neutrophil-to-lymphocyte ratio (d-NLR) were significantly higher in severe forms of COVID-19. The ROC curve analysis showed that IL6 was the most accurate inflammatory biomarker. The calculated cutoff of IL6 (42 pg/ml) could correctly classify > 90% of patients regarding their risk of severity (area under ROC curve (AUROC) = 0.972) and the threshold value of 83 pg/ml was highly predictive of the progression to death (AUROC = 0.94, OR = 184) after a median of 3 days. Besides, IL-6 was positively correlated with other inflammatory markers and the kinetic analysis highlighted its value for monitoring COVID-19 patients. PCT and NLR had also a high prognostic relevance to assess severe forms of COVID-19 with corresponding AUROC of 0.856, 0.831 respectively. Furthermore the cut-off values of PCT (0.16 ng/ml) and NLR (7.4) allowed to predict mortality with high accuracy (se = 96.3%, sp = 70.5%,OR = 61.2)' (se = 75%, sp = 84%, OR = 14.6).The levels of these parameters were not influenced by corticosteroid treatment, which make them potential prognostic markers when patients are already undergoing steroid therapy.

Identifiants

pubmed: 33550165
pii: S1043-4666(21)00008-9
doi: 10.1016/j.cyto.2021.155428
pmc: PMC7834734
pii:
doi:

Substances chimiques

Adrenal Cortex Hormones 0
Biomarkers 0
IL2RA protein, human 0
IL6 protein, human 0
Inflammation Mediators 0
Interleukin-2 Receptor alpha Subunit 0
Interleukin-6 0
Procalcitonin 0
C-Reactive Protein 9007-41-4
Ferritins 9007-73-2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

155428

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Références

J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Clin Infect Dis. 2021 Jun 1;72(11):e695-e703
pubmed: 32945846
J Infect. 2020 Jul;81(1):e6-e12
pubmed: 32283162
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Aging Cell. 2020 Jul;19(7):
pubmed: 32558150
Lancet Respir Med. 2014 Aug;2(8):611-20
pubmed: 24853585
Intensive Care Med. 2018 Nov;44(11):1859-1869
pubmed: 30291376
Immunol Lett. 2020 Sep;225:31-32
pubmed: 32569607
Int Immunopharmacol. 2020 Jul;84:106504
pubmed: 32304994
Clin Chim Acta. 2020 Jun;505:190-191
pubmed: 32145275
Int J Infect Dis. 2020 Jun;95:332-339
pubmed: 32334118
Immunol Invest. 2021 Jan;50(1):92-100
pubmed: 32482134
Zhonghua Bing Li Xue Za Zhi. 2020 May 8;49(5):411-417
pubmed: 32172546
Am J Respir Crit Care Med. 2017 Feb 1;195(3):331-338
pubmed: 27513822
Breathe (Sheff). 2019 Dec;15(4):296-304
pubmed: 31803264
Cold Spring Harb Perspect Biol. 2014 Sep 04;6(10):a016295
pubmed: 25190079
J Pharm Anal. 2020 Apr;10(2):102-108
pubmed: 32282863
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
J Med Virol. 2020 Jul;92(7):856-862
pubmed: 32281668
Clin Infect Dis. 2020 Nov 19;71(16):2174-2179
pubmed: 32445579
Science. 2020 May 1;368(6490):473-474
pubmed: 32303591
Emerg Microbes Infect. 2020 Dec;9(1):1123-1130
pubmed: 32475230
J Med Virol. 2020 Jul;92(7):791-796
pubmed: 32181911
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
J Clin Virol. 2020 Jun;127:104370
pubmed: 32344321
Expert Rev Anti Infect Ther. 2018 Jul;16(7):555-564
pubmed: 29969320
JCI Insight. 2020 May 21;5(10):
pubmed: 32324595
Sci Rep. 2015 Jun 16;5:11355
pubmed: 26079127
J Transl Med. 2020 May 20;18(1):206
pubmed: 32434518
J Immunol. 2008 Aug 1;181(3):2189-95
pubmed: 18641358
J Infect. 2020 Sep;81(3):452-482
pubmed: 32526326
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
J Allergy Clin Immunol. 2020 Jul;146(1):128-136.e4
pubmed: 32425269
Nat Med. 2020 Jul;26(7):1070-1076
pubmed: 32514174
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Med Virol. 2020 Nov;92(11):2283-2285
pubmed: 32343429
J Clin Invest. 2020 Sep 1;130(9):4694-4703
pubmed: 32463803
Cell Death Differ. 2020 May;27(5):1451-1454
pubmed: 32205856
Int J Antimicrob Agents. 2020 Aug;56(2):106017
pubmed: 32437920

Auteurs

Wafa Sayah (W)

Immunology Department, Beni-Messous Teaching Hospital, University of Algiers 1, Algeria.

Ismahane Berkane (I)

Immunology Department, Beni-Messous Teaching Hospital, University of Algiers 1, Algeria.

Imène Guermache (I)

Immunology Department, Beni-Messous Teaching Hospital, University of Algiers 1, Algeria.

Mohamed Sabri (M)

Immunology Department, Beni-Messous Teaching Hospital, University of Algiers 1, Algeria.

Fatma Zahra Lakhal (FZ)

Immunology Department, Beni-Messous Teaching Hospital, University of Algiers 1, Algeria.

Sarah Yasmine Rahali (S)

Immunology Department, Beni-Messous Teaching Hospital, University of Algiers 1, Algeria.

Asma Djidjeli (A)

Immunology Department, Beni-Messous Teaching Hospital, University of Algiers 1, Algeria.

Lydia Lamara Mahammed (L)

Immunology Department, Beni-Messous Teaching Hospital, University of Algiers 1, Algeria.

Fatma Merah (F)

Immunology Department, Beni-Messous Teaching Hospital, University of Algiers 1, Algeria.

Brahim Belaid (B)

Immunology Department, Beni-Messous Teaching Hospital, University of Algiers 1, Algeria.

Lilya Berkani (L)

Immunology Department, Beni-Messous Teaching Hospital, University of Algiers 1, Algeria.

Nouzha Zhor Lazli (NZ)

Immunology Department, Beni-Messous Teaching Hospital, University of Algiers 1, Algeria.

Lylia Kheddouci (L)

Immunology Department, Beni-Messous Teaching Hospital, University of Algiers 1, Algeria.

Ahmed Kadi (A)

Pneumology Department A, Béni-Messous Teaching Hospital, University of Algiers 1, Algeria.

Mourad Ouali (M)

Intensive Care Department Beni-Messous Teaching Hospital, University of Algiers 1, Algeria.

Rachida Khellafi (R)

Pneumology Department B, Béni-Messous Teaching Hospital, University of Algiers 1, Algeria.

Dalila Mekideche (D)

Pneumology Department C, Béni-Messous Teaching Hospital, University of Algiers 1, Algeria.

Assia Kheliouen (A)

Pneumology Department A, Béni-Messous Teaching Hospital, University of Algiers 1, Algeria.

Réda Malek Hamidi (RM)

Intensive Care Department Beni-Messous Teaching Hospital, University of Algiers 1, Algeria.

Soraya Ayoub (S)

Internal Medicine Department Beni-Messous, Teaching Hospital, University of Algiers 1, Algeria.

Nabil Beramtane Raaf (NB)

Biology Department, Birtraria Hospital, Algiers, Algeria.

Fawzi Derrar (F)

Virology Department, Institut Pasteur d'Algérie, Algiers, Algeria.

Merzak Gharnaout (M)

Pneumology Department, Rouiba Hospital, University of Algiers 1, Algeria.

Ines Allam (I)

Immunology Department, Beni-Messous Teaching Hospital, University of Algiers 1, Algeria.

Réda Djidjik (R)

Immunology Department, Beni-Messous Teaching Hospital, University of Algiers 1, Algeria. Electronic address: ourtilane@yahoo.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH